NASDAQ:HSCS

HeartSciences Q3 2025 Earnings Results & Report

HeartSciences logo
$2.06 -0.02 (-0.96%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$2.24 +0.18 (+8.79%)
As of 07:35 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

HeartSciences missed analyst earnings expectations in its Q3 2025 results, released March 13, 2025. The company reported EPS of -$2.5722 versus the -$2.53 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2025
Report Date
Time
Before Market Opens
Conference Call
8:00 AM ET

HeartSciences EPS Results

Actual EPS
-$2.5722
Consensus EPS
-$2.53
Beat/Miss
Missed by -$0.0422
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

HeartSciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

HeartSciences' Q2 2027 earnings is estimated for Monday, December 21, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, December 16, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

HeartSciences Q3 2025 Earnings FAQ

HeartSciences (NASDAQ:HSCS) reported earnings of -$2.5722 per share for Q3 2025, missing the consensus estimate of -$2.53. The report was announced on Thursday, March 13, 2025.

HeartSciences' next earnings date is estimated for Monday, December 21, 2026. MarketBeat tracks confirmed and estimated earnings dates for HeartSciences on the company's earnings history page.

HeartSciences Earnings Headlines

What the hell is going on?
Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and the shift is already underway. The dollar has lost 88% of its purchasing power since it was untethered from gold, and Fortune calls the current change the biggest shift in the world's relationship with the dollar in a generation. Stansberry says a similar reset is planned to be unveiled in Miami as soon as this December. Watch Porter Stansberry's full broadcast to see which companies could be affected.tc pixel
See More HeartSciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like HeartSciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on HeartSciences and other key companies, straight to your email.

About HeartSciences

HeartSciences (NASDAQ:HSCS) develops medical technology intended to help healthcare professionals detect heart conditions using electrocardiograms (ECGs). The company combines ECG testing with software-based analysis to support the assessment of cardiac function.

Its MyoVista wavECG device is designed to perform standard ECG testing while also analyzing the heart’s electrical signals for information that may help identify dysfunction, including diastolic dysfunction. The company’s offerings are aimed at clinical settings where ECGs are used to evaluate patients’ heart health.

HeartSciences focuses on developing and commercializing these technologies for healthcare providers. Its products are intended to complement existing diagnostic workflows; medical professionals determine how results are interpreted and used in patient care.

View HeartSciences Profile